Physician profile
Christopher Foote
NPI 1912310442
$3,677.32
in general payments reported to CMS, 2019-2025
28 companies · $675 in 2025
The $675 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $340 · 2020: $161 · 2021: $455 · 2022: $262 · 2023: $929 · 2024: $856 · 2025: $675.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,459.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $969.57 | 2021-2024 | Axonics, Bulkamid |
| Boston Scientific Corporation | $366.89 | 2019-2024 | Lithovue |
| Sumitomo Pharma America, INC. | $260.65 | 2023-2025 | Gemtesa |
| Procept Biorobotics Corporation | $236.76 | 2019-2025 | |
| Pfizer INC. | $205.33 | 2021-2025 | |
| Olympus America INC. | $179.92 | 2021-2025 | Itind System |
| Abbvie INC. | $142.63 | 2022-2025 | |
| Astellas Pharma US INC | $129.66 | 2019-2024 | Xtandi |
| Intuitive Surgical, INC. | $121.18 | 2020-2024 | Da Vinci Surgical System |
| Blue Earth Diagnostics | $114.70 | 2019 | |
| Ferring Pharmaceuticals INC. | $105.66 | 2024-2025 | Adstiladrin |
| Tolmar, INC. | $101.82 | 2023-2025 | Jatenzo |
| Endo USA, INC. | $96.64 | 2024-2025 | Xiaflex |
| Myriad Genetic Laboratories, INC. | $85.38 | 2023-2025 | Myrisk, Prolaris |
| Endo Pharmaceuticals INC. | $85.31 | 2023-2024 | Xiaflex |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ambu INC. | $74.84 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $72.13 | 2019-2025 | |
| C. R. Bard, INC. & Subsidiaries | $54.10 | 2023-2024 | Bard Urinary Drainage Bag |
| Progenics Pharmaceuticals, INC. | $51.37 | 2024 | |
| Rochester Medical Corporation | $41.01 | 2021-2022 | |
| 180 Medical, INC. | $40.34 | 2022-2023 | Cure Ultra Catheter |
| Genzyme Corporation | $30.67 | 2022 | |
| Merck Sharp & Dohme LLC | $22.55 | 2023 | Lynparza, Keytruda |
| Urovant Sciences INC | $21.40 | 2022 | |
| Halozyme INC | $18.81 | 2023 | |
| Mimedx Group, INC. | $18.62 | 2025 | |
| Allergan, INC. | $16.52 | 2022 | |
| Kci USA, INC. | $12.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Foote listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.